Use of hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a biomarker for renal injury or renal disease

US8460884B2 · kind B2 · utility

Assignee

• Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center · US

Inventors

• Sharon Adler · Los Angeles, US
• Tiane Dai · Torrance, US
• Ying Wang · South Setauket, US
• Mukti Patel-Chamberlin · Torrance, US
• Cynthia C. Nast · Rancho Palos Verdes, US
• Janine LaPage · Redondo Beach, US
• Nosratolah Dabir Vaziri · Newport Beach, US
• Madeleine V. Pahl · Orange, US

Key dates

• Filing date: Nov 5, 2009
• Grant date: Jun 11, 2013
• Expiry date: May 2, 2031

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/347
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.